Arexvy RSV Vaccine Shows Protection Over Three Seasons
Cumulative efficacy over three RSV seasons was clinically meaningful at 62.9% against RSV-LRTD after a single dose of the vaccine.Â
Tag: RSV respiratory syncytial virus
All
Latest
All
Latest
Merck’s Investigational RSV Shot Protects Infants in Phase 2b/3 Trial
The trial showed that clesrovimab reduced RSV-related respiratory infections in infants through day 150.
All
Latest
Tool Identifies Newborns at Highest Risk for Severe RSV
Researchers have created a new tool to identify newborns at the highest risk for severe RSV, enhancing the prioritization of immunoprophylaxis during shortages.
Pfizer’s RSV Vaccine Protective Through Two Seasons in Older Adults
New top-line results show the bivalent vaccine maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose.
Read More
Sequential Flu and Measles-like Virus Infections Trigger Deadly Lung Failure
Georgia State University researchers discover that ferrets recovering from flu-like viruses suffer lethal lung damage when subsequently infected with a measles-like virus.
Read More
Rising Respiratory Illnesses Leading to More Heart Complications
The recent surge in influenza, COVID-19, and other respiratory viruses can trigger cardiovascular complications from fever, dehydration, and increased inflammation, and Mount Sinai doctors are seeing a rise in these cases in all age groups.
Read More
Gut Microbiota Influence Severity of Viral Infections
The composition of microbiota found in the gut influences how susceptible mice are to respiratory virus infections and the severity of these infections.
Read More
10 States Where Nighttime Coughs Are Keeping People Awake
Sleep tracking app Sleep Cycle analyzed over 2 million hours of sleep to understand how coughing may be affecting users’ sleep health.Â
Read More
RSV Vaccine Added to ACIP 2024 Adult Immunization ScheduleÂ
The Advisory Committee on Immunization Practices has released its 2024 Recommended Adult Immunization Schedule which includes four new vaccines.Â
Read More
The Tripledemic Is Surging
Hospital systems across the country are reporting more and more cases of RSV, COVID-19 and influenza as the seasonal Tripledemic is surging.
Read More
RSV Can Infect Nerve Cells and Enter Spinal Cord
Long thought to only infect the respiratory tract, a new study has found that RSV can infect nerve cells, cause nerve damage, and enter the spinal cord, potentially granting access to the central nervous system.
Read More
Canada Approves Pfizer’s RSV Vaccine
The vaccine was approved for older adults and infants through maternal immunization.Â
Read More
Full RSV Vaccination Could Cut Senior Hospitalizations by 91.7%
Respiratory syncytial virus vaccines recently approved for people 60 and older would dramatically reduce the disease’s burden of illness and death if they were widely adopted like annual influenza vaccines, a Yale University study finds.
Read More
Beyfortus Approved in China to Prevent RSV Infants
AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.
Read More
One-third of Americans Unconcerned with Infectious Disease Risk
Despite the Centers for Disease Control and Prevention warning this year will be potentially dangerous for respiratory illnesses, a third of Americans are not concerned about the threat, according to a new national survey by The Ohio State University Wexner Medical Center.
Read More